Loading
FGL1 is a liver protein that some tumours secrete; it binds LAG-3 on T cells and switches them off, separately from the MHC class II route. It explains part of how LAG-3 blockade works. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
A secreted fibrinogen-family protein; the second LAG-3 ligand after MHC class II.
No product in the corpus is aimed at this target yet.
No trial in the corpus names this target or one of its products.
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"FGL1" OR ABSTRACT:"FGL1" OR TITLE:"fibrinogen like 1" OR ABSTRACT:"fibrinogen like 1" OR TITLE:"HFREP-1" OR ABSTRACT:"HFREP-1" OR TITLE:"hepassocin" OR ABSTRACT:"hepassocin") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FGL1, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/fgl1.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/fgl1.json. Licence CC BY-NC 4.0.